Technology | Mammography | January 24, 2017

FDA Approves Fujifilm's 3-D Mammography

U.S. customers now have access to optional tomosynthesis software upgrade for Aspire Cristalle full field digital mammography system

Fujifilm, Aspire Cristalle full field digital mammography system, digital breast tomosynthesis, DBT software upgrade, FDA approval

January 24, 2017 — Fujifilm Medical Systems U.S.A. Inc. announced that its Digital Breast Tomosynthesis (DBT) software upgrade for its Aspire Cristalle digital mammography system, has received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA). The optional DBT upgrade is now available in the United States.

Radiologists using the Aspire Cristalle full field digital mammography (FFDM) system with DBT will realize enhanced clinical efficiency compared to using FFDM alone. This includes superior diagnostic accuracy and lower recall rates for non-cancer cases, according to Fujifilm.

Known as Amulet Innovality outside of the United States, the optional DBT upgrade has been widely available in Europe, Asia and Latin America since May 2013. The Aspire Cristalle FFDM system with DBT combines Fujifilm’s hexagonal close pattern (HCP) detector design, advanced image processing and image acquisition workflow to optimize patient dose while maximizing image quality.

With the DBT software option, the X-ray tube moves through an arc around the breast, acquiring a series of low-dose image slices at different angles, producing a three-dimensional view allowing radiologists to see through tissue less obstructed. The acquired images are reconstructed into a series of high-resolution 1 millimeter slices displayed individually or dynamically in a cine mode — making it easier to identify lesions that might be difficult to see in traditional 2-D mammography images due to overlapping breast structures. This will bring a new level of diagnostic confidence in screening, and especially for those women with dense breast tissue who are at higher than average risk and more difficult to screen with traditional 2-D only.

The Aspire Cristalle FFDM system with DBT will be on display at the National Consortium of Breast Centers (NCoBC) conference, March 11-13, 2017 in Las Vegas, and the Society of Breast Imaging (SBI) Symposium, April 6-9, 2017, in Los Angeles.

For more information: www.fujimed.com

Related Content

RSNA Study Shows Real-Time Indicator Improves Mammographic Compression
News | Mammography | December 12, 2018
Sigmascreening recently announced that more than 100,000 women have had mammography exams with the Sensitive Sigma...
Massachusetts Superior Court Grants Hologic Preliminary Injunction in Trade Secrets Lawsuits
News | Mammography | December 12, 2018
December 12, 2018 — A Massachusetts Superior Court granted a preliminary injunction in lawsuits by Hologic against Ch
Videos | Mammography | December 10, 2018
Stamatia Destounis, M.D., FACR, associate professor, University of Rochester School of Medicine, and attending radiol
FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis
Technology | Mammography | December 07, 2018
iCAD Inc. announced clearance by the U.S. Food and Drug Administration (FDA) for their latest, deep-learning, cancer...
Fujifilm Collaborates With Lunit on AI Pilot Project
News | Artificial Intelligence | December 05, 2018
Fujifilm Medical Systems USA Inc. announced a joint collaboration with Korean-based medical artificial intelligence (AI...
ScreenPoint Medical and Volpara Partner to Bring AI to Breast Imaging Clinics
News | Computer-Aided Detection Software | December 04, 2018
ScreenPoint Medical has signed a memorandum of understanding (MOU) with Volpara Health Technologies. Volpara will...
GE Healthcare Introduces Invenia ABUS 2.0
Technology | Ultrasound Women's Health | December 03, 2018
GE Healthcare recently launched the Invenia automated breast ultrasound (ABUS) 2.0 system in the United States. This...
Snoring Poses Greater Cardiac Risk to Women
News | Women's Health | November 29, 2018
Obstructive sleep apnea (OSA) and snoring may lead to earlier impairment of cardiac function in women than in men,...
ScreenPoint Medical Receives FDA Clearance for Transpara Mammography AI Solution
Technology | Computer-Aided Detection Software | November 28, 2018
November 28, 2018 — ScreenPoint Medical announced it has received 510(k) clearance from the U.S.
Women Benefit From Mammography Screening Beyond Age 75
News | Mammography | November 26, 2018
Women age 75 years and older should continue to get screening mammograms because of the comparatively high incidence of...